| Literature DB >> 2571860 |
Y Brewer1, A Palmer, D Taube, K Welsh, M Bewick, C Bindon, G Hale, H Waldmann, F Dische, V Parsons.
Abstract
In a blind trial, 77 patients were randomised to receive first cadaver kidney allografts that had been perfused either with a pair of CD45 monoclonal antibodies (mAbs), in an attempt to reduce the immunogenicity of passenger leucocytes, or with control human albumin solution. No complications of mAb perfusion were observed. Patient and allograft survival were similar in both groups. Rejection episodes were recorded in 7 (18%) of the patient with mAb perfused allografts compared with 24 (63%) of the controls.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2571860 DOI： 10.1016/s0140-6736(89)90951-3
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321